Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of AKP-021 in Healthy Male Adults
jRCT2071250093Phase 1Recruiting
- Sponsor
- ASKA Pharmaceutical Holdings Co., Ltd.
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AKP-021 (24 arms), sponsored by ASKA Pharmaceutical Holdings Co., Ltd. Primary endpoints: Safety, Pharmacokinetics and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
AKP-021
Beyond the preview
Go deeper on jRCT2071250093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250093.